Clinical Trial Detail

NCT ID NCT02112916
Title Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

precursor T-lymphoblastic lymphoma/leukemia

acute T cell leukemia

Therapies

Cyclophosphamide

Vincristine

Ifosfamide

Pegaspargase

Methotrexate

Cytarabine

Mercaptopurine

Thioguanine

Leucovorin

Daunorubicin

Dexamethasone

Bortezomib

Etoposide

Doxorubicin

Age Groups: adult child

No variant requirements are available.